Date: 2012-06-14
Type of information: Commercialisation agreement
Compound: Veregen® ointment (made from the extract of green tea leaves - catechins)
Company: Medigene (Germany) Azanta (Denmark)
Therapeutic area: Infectious diseases - Gynecology - Women's health
Type agreement: supply
commercialisation
Action mechanism:
Disease: genital and perianal wart
Details: Medigene and Azanta, a Danish specialty pharma company with focus on oncology, women\'s healthcare and addiction medicine, have concluded an exclusive agreement for the supply and marketing of Veregen® for the treatment of genital and perianal warts in Denmark, Sweden, Norway, Finland, and Iceland.
Azanta is planning to launch Veregen® in Denmark, Sweden, Finland, and Norway in early 2013. Marketing authorization applications for these and several other European countries were positively assessed by the respective regulatory authorities in March 2012. Market approvals for Sweden and Norway have already been granted, and Medigene anticipates that the other national marketing authorizations will be formally granted within the next few months. The marketing authorization applications for Iceland and several other countries are in preparation.
Financial terms: Medigene will benefit from a one-time upfront payment, the supply of the finished product as well as double-digit royalties on sales of Veregen® in these countries.
Latest news:
